The Journal of the Pharmacy Society of Wisconsin
  • Home
  • Past Issues
    • Journal Archives
    • JPSW 2025
    • JPSW 2024
    • JPSW 2023
    • JPSW 2022
    • JPSW 2021
    • JPSW 2020
    • JPSW 2019
    • JPSW 2018
    • JPSW 2017
  • JPSW Supplements
  • Open-Access Series
    • Preceptor Development Series
    • Statistics Review Series
  • For Authors and Reviewers
    • Author Guidelines
    • CE Author Guidelines
    • Case Report Author Guidelines
    • Types of Manuscripts
    • Peer Review Information
    • Emerging Writers Course
    • Submit a Manuscript
  • Contact
    • Editorial Advisory Committee

​ID Corner: ​Remdesivir in the Treatment of Hospitalized Patients with COVID-19: Evolution of Use Over the Course of the Pandemic

by Lauren N. Nevinski, PharmD, Lynne Fehrenbacher, PharmD, BCPS-AQ ID, Thomas J Dilworth, PharmD, BCPS-AQ ID 
​

"Since the beginning of the COVID-19 pandemic, significant effort has been directed towards optimizing pharmacologic treatment for patients hospitalized with SARS-CoV-2. Over the course of the past year, several drug classes have been used with limited success in an attempt to treat COVID-19. The World Health Organization (WHO) treatment guidelines have evolved based on ongoing clinical trials with various agents, including, but not limited to, remdesivir (Veklury®, Gilead). A continued debate about using remdesivir has been defining which group of hospitalized patients, as categorized by the WHO COVID-19 disease severity ordinals (Table 1), are likely to benefit the most given the varying results published from clinical evidence.1 An ordinal, or ordinal number, defines an individual’s position or category in a list, to make generalized interpretation easier in clinical studies."

Keywords: Remdesivir, RNA, Viral, Alanine Transaminase, COVID-19, SARS-CoV-2, RNA-Dependent RNA Polymerase, Pharmaceutical Preparations, Viral Load, Adenosine Triphosphate, Pandemics, United States Food and Drug Administration, Double-Blind Method, COVID-19 drug treatment, Respiration, Artificial, Length of Stay, Partial Pressure, Virus Replication, Contraindications, World Health Organization, Severity of Illness Index

​Download PDF 

2021 September/October Table of Contents 

The Journal of the Pharmacy Society of Wisconsin (ISSN 2837-8229)


Past Issues

2025
2024

2
023
2020
2021
​2022
2019
2018
2017

About PSW

www.pswi.org

Contact Us

[email protected]
  • Home
  • Past Issues
    • Journal Archives
    • JPSW 2025
    • JPSW 2024
    • JPSW 2023
    • JPSW 2022
    • JPSW 2021
    • JPSW 2020
    • JPSW 2019
    • JPSW 2018
    • JPSW 2017
  • JPSW Supplements
  • Open-Access Series
    • Preceptor Development Series
    • Statistics Review Series
  • For Authors and Reviewers
    • Author Guidelines
    • CE Author Guidelines
    • Case Report Author Guidelines
    • Types of Manuscripts
    • Peer Review Information
    • Emerging Writers Course
    • Submit a Manuscript
  • Contact
    • Editorial Advisory Committee